Polysan, Ltd.   Report issue

For profit Phase 2 Phase 3
Founded: Saint Petersburg Russian Federation (1992)

Organization Overview

First Clinical Trial
2016
NCT03028285
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

POLYSAN Scientific & Technological Pharmaceutical Company | Scientific Technological Pharmaceutical Firm Polysan, Ltd. | STPF POLYSAN

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cognitive Dysfunction (Phase 3)

Craniocerebral Trauma (Phase 3)

Diabetic Neuropathies (Phase 3)

Fatty Liver (Phase 2)

Head Injuries, Closed (Phase 3)

Jaundice (Phase 3)

Jaundice, Obstructive (Phase 3)

Liver Diseases (Phase 2)

Non-alcoholic Fatty Liver Disease (Phase 2)

Peripheral Arterial Disease (Phase 2)

Peripheral Vascular Diseases (Phase 2)

Polyneuropathies (Phase 3)

Vascular Diseases (Phase 1)

Wounds and Injuries (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 12
  • # of Trial APIs: 10